Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06895746 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multi-omics Study in Citrin Deficiency

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study description expanded, about 1 wordv4
  2. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Dec 2025 to Jun 2026
    • Study completion date: Dec 2025 to Dec 2026
    • Site details revised at 23 of 23 sites
    v3
  3. Secondary endpoints: details revised at 1 of 1 entry
    • Study description shortened, about 7 words
    • Site details revised at 2 of 23 sites
    • Collaborators: 23 to 24
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Citrin deficiency (CD) is an underdiagnosed and understudied condition characterized by several distinct phenotypes: 1) neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), 2) the adaptation or silent period, 3) "failure to thrive and dyslipidemia" form of CD (FTTDCD), and 4) citrullinemia type II (CTLN2), with the latter representing the final and most severe form of the condition. There is currently no cure for CD and patients manage their symptoms with lifelong dietary intervention and regular checkups with their physicians. A major hurdle in developing effective treatments for CD is the lack of effective biomarkers that track well with disease severity or measure the effectiveness of therapeutics. The present study aims to identify robust circulating biomarkers of CD through analysis of blood samples from CD patients.
Trial Details
NCT Number NCT06895746
Lead Sponsor Johannes Haeberle
Collaborators: Citrin Foundation, Bristol Royal Hospital for Children, Manchester University NHS Foundation Trust, University Hospital Birmingham NHS Foundation Trust, Northern Care Alliance NHS Foundation Trust, Mount Sinai Hospital, New York, National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Pusan National University Yangsan Hospital, Saitama Medical University, Osaka Metropolitan University, Tohoku University, Kurume University, University College London Hospitals, Sheffield Children's NHS Foundation Trust, Great Ormond Street Hospital for Children NHS Foundation Trust, Kumamoto University, Saiseikai Yokohama City Eastern Hospital, Jikei University School of Medicine, Yamagata University, Chiba Children's Hospital, Shinshu University Hospital, Birmingham Women's and Children's NHS Foundation Trust, National Hospital Organisation Hokkaido Medical Center
Conditions
(from sponsor)		 Citrin Deficiency
Related terms Adult-onset citrullinemia type 2
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov